Zimmer Biomet Holdings Inc (ZBH) Expected to Post Earnings of $2.10 Per Share
Analysts expect Zimmer Biomet Holdings Inc (NYSE:ZBH) to announce earnings per share (EPS) of $2.10 for the current fiscal quarter, Zacks reports. Eleven analysts have issued estimates for Zimmer Biomet’s earnings. The lowest EPS estimate is $2.07 and the highest is $2.13. Zimmer Biomet reported earnings of $2.14 per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 1.9%. The business is scheduled to issue its next quarterly earnings report on Tuesday, January 30th.
According to Zacks, analysts expect that Zimmer Biomet will report full-year earnings of $8.03 per share for the current year, with EPS estimates ranging from $8.00 to $8.05. For the next fiscal year, analysts forecast that the company will report earnings of $8.18 per share, with EPS estimates ranging from $8.00 to $8.50. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that cover Zimmer Biomet.
Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Wednesday, November 1st. The medical equipment provider reported $1.72 EPS for the quarter, missing the consensus estimate of $1.74 by ($0.02). Zimmer Biomet had a net margin of 8.36% and a return on equity of 16.29%. The business had revenue of $1.82 billion during the quarter, compared to analyst estimates of $1.83 billion. During the same period in the previous year, the business posted $1.79 earnings per share. The firm’s revenue for the quarter was down .8% on a year-over-year basis.
A number of analysts have recently issued reports on ZBH shares. Jefferies Group reaffirmed a “buy” rating and issued a $136.00 price target on shares of Zimmer Biomet in a research note on Friday, November 3rd. Stifel Nicolaus reaffirmed a “hold” rating and issued a $120.00 price target on shares of Zimmer Biomet in a research note on Friday, November 3rd. SunTrust Banks reaffirmed a “buy” rating and issued a $136.00 price target on shares of Zimmer Biomet in a research note on Monday, October 2nd. TheStreet lowered Zimmer Biomet from a “b-” rating to a “c+” rating in a research note on Friday, November 24th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zimmer Biomet in a research note on Friday, January 5th. Two research analysts have rated the stock with a sell rating, five have given a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $137.42.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Private Advisor Group LLC raised its position in Zimmer Biomet by 18.6% in the third quarter. Private Advisor Group LLC now owns 6,733 shares of the medical equipment provider’s stock valued at $791,000 after purchasing an additional 1,057 shares during the period. Ingalls & Snyder LLC raised its position in Zimmer Biomet by 2.6% in the third quarter. Ingalls & Snyder LLC now owns 19,675 shares of the medical equipment provider’s stock valued at $2,304,000 after purchasing an additional 507 shares during the period. Koch Industries Inc. raised its position in Zimmer Biomet by 49,697.3% in the second quarter. Koch Industries Inc. now owns 1,040,764 shares of the medical equipment provider’s stock valued at $1,033,000 after purchasing an additional 1,038,674 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its position in Zimmer Biomet by 10.0% in the third quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 16,444 shares of the medical equipment provider’s stock valued at $1,925,000 after purchasing an additional 1,494 shares during the period. Finally, WINTON GROUP Ltd purchased a new stake in Zimmer Biomet in the third quarter valued at $370,000. 85.92% of the stock is currently owned by institutional investors.
Shares of Zimmer Biomet (ZBH) opened at $122.10 on Monday. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.47 and a quick ratio of 0.78. Zimmer Biomet has a 1-year low of $108.03 and a 1-year high of $133.49. The company has a market capitalization of $24,721.95, a P/E ratio of 38.40, a price-to-earnings-growth ratio of 1.90 and a beta of 1.15.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, January 29th. Shareholders of record on Friday, December 29th will be paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 0.79%. The ex-dividend date is Thursday, December 28th. Zimmer Biomet’s dividend payout ratio (DPR) is currently 30.19%.
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.